Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line Stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

M.W. Tang, S.Y. Rhee, S. Bertagnolio, N. Ford, S. Holmes, K.C. Sigaloff, R.L. Hamers, T.F. Rinke de Wit, H.J. Fleury, P.J. Kanki, K. Ruxrungtham, C.A. Hawkins, C.L. Wallis, W. Stevens, G.U. van Zyl, W. Manosuthi, M.C. Hosseinipour, N. Ngo-Giang-Huong, L. Belec, M. PeetersA. Aghokeng, T. Bunupuradah, S. Burdah, P. Cane, G. Cappelli, C. Charpentier, A.Y. Dagnra, A.K. Deshpande, Z. El-Katib, S.H. Eshleman, J. Fokam, J.C. Gody, D. Katzenstein, D.D. Koyalta, J.J. Kumwenda, M. Lallemant, L. Lynen, V.C. Marconi, N.A. Margot, S. Moussa, T. Ndung'u, P.N. Nyambi, C. Orrell, J.M. Schapiro, R. Schuurman, S. Sirivichayakul, D. Smith, M. Zolfo, M.R. Jordan, R.W. Shafer

Research output: Contribution to journalA1: Web of Science-article

Original languageEnglish
JournalJournal of Infectious Diseases
Volume207
Issue numberS2
Pages (from-to)S70-S77
ISSN0022-1899
DOIs
Publication statusPublished - 2013

Keywords

  • Viral diseases
  • HIV
  • AIDS
  • HAART
  • Antiretrovirals
  • First-line drugs
  • Mutations
  • Nucleoside
  • Reverse transcriptase inhibitors
  • Drug resistance
  • Stavudine
  • Zidovudine
  • Tenofovir
  • Efavirenz
  • Duration
  • Review of the literature

Cite this